What is TNXP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TNXP?

P/E (TTM) is n/a and 52-week range is $7.09 to $23.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TNXP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TNXP?

The company profile lists revenue (TTM) near $28M, net income (TTM) near $-15.30B, EPS (TTM) near $-12.92 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tonix Pharmaceuticals Holding Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Chatham, New Jersey, US, 15.9M shares outstanding, ISIN US8902608392 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Tonix Pharmaceuticals Holding Corp

$TNXP

Health Care · Biotechnology

IR Run Scenarios

$7.30

+0.27%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 142 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Employees

142

Website

www.tonixpharma.com/

IPO

2010-03-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)